Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

292 ta ish

Ish: CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

  1. CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer

    Y-C Wu, S‐J. Tang, G-H Sun +1

    Maqola20152 iqtibos
    ABI

  2. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

    Julia Hoellenriegel, Dirk Zboralski, Christian Maasch +5

    Maqola20132 iqtibos
    ABI

  3. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway

    Zhongxing Liang, Joann Brooks, Margaret Willard +4

    Maqola20072 iqtibos
    ABI

  4. CXCR4–SDF-1 Signalling, Locomotion, Chemotaxis and Adhesion

    Magda Kucia, Kacper Jankowski, Ryan Reca +6

    Sharh maqola20042 iqtibos
    ABI

  5. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis

    Linhui Wang, Liang Wang, Bo Yang +4

    Maqola20092 iqtibos
    ABI

  6. CXCR4: A virus’s best friend?

    Kathleen L. Arnolds, Juliet V. Spencer

    Sharh maqola20142 iqtibos
    ABI

  7. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

    Beverly A. Teicher, Simon P. Fricker

    Sharh maqola20102 iqtibos
    ABI

  8. Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor

    Yan Wang, Yihua Chen, J. Wang +4

    Maqola20122 iqtibos
    ABI

  9. The significance of cancer cell expression of the chemokine receptor CXCR4

    Frances R. Balkwill

    Sharh maqola20042 iqtibos
    ABI

  10. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

    Xueqing Sun, Guangcun Cheng, Mingang Hao +6

    Sharh maqola20102 iqtibos
    ABI

  11. Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment

    Stefania Scala

    Sharh maqola20152 iqtibos
    ABI

  12. Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>

    Katia Beider, Merav Darash‐Yahana, Orly Blaier +8

    Maqola20142 iqtibos
    ABI

  13. Involvement of chemokine receptors in breast cancer metastasis

    Anja Müller, Bernhard Homey, Hortensia Soto +11

    Maqola20012 iqtibos
    ABI

  14. Small Molecule Inhibitors of CXCR4

    Bikash Debnath, Shili Xu, Fedora Grande +2

    Sharh maqola20132 iqtibos
    ABI

  15. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors

    Anneleen Van Hout, Thomas D’huys, Merel Oeyen +2

    Maqola20172 iqtibos
    ABI

  16. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

    Weiqiang Zhou, Shanchun Guo, Mingli Liu +2

    Sharh maqola20172 iqtibos
    ABI

  17. Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer

    Niels Halama, Ulrike Prüfer, Anna Froemming +4

    Maqola20192 iqtibos
    ABI

  18. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions

    Christine Huynh, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen +1

    Sharh maqola20202 iqtibos
    ABI

  19. The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

    Yi Shi, David J. Riese, Jianzhong Shen

    Sharh maqola20202 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI